Tagged with Pfizer

Italy The top 10 pharma manufacturing companies in Italy, as collated by MonitorItalia and ranked by production value in 2022. Pfizer tops the list, followed by Novartis, and local player Chiesi. The remainder of the list is populated by familiar names from multinational pharma, although another Italian firm – Alfasigma –…

Global Pfizer CEO Albert Bourla’s ‘annus horribilis’ shows no sign of abating. From being feted as the industry darling of the COVID-19 period, Pfizer management is now being accused of USD 20 billion worth of “value destruction” by activist investors. As new analysis shows, Bourla has also suffered the ignominy of…

USA Naming a Chief Artificial Intelligence (AI) officer may not be an industry first, but Lilly’s recent creation of the role with the appointment of Thomas Fuchs confirms the solid commitment pharma has already made to introducing AI in processes that range from drug discovery to marketing.   AI Leaders Eli…

UAE Pfizer has a new regional president for its vast Middle East, Russia and Africa (MERA) country grouping. Turkish national Elif Aral, a 29-year Pfizer veteran, will take over from Patrick van der Loo, who becomes Pfizer Germany’s country president.   The Context This is a challenging and diverse region, where…

Mexico This year has seen no less than five GM changes at international pharma companies’ Mexican affiliates. Pfizer, MSD, Roche, Sanofi and Gilead have all taken on new local leadership. In some cases, the appointments represent a first for affiliates that have never had female leaders while in others they coincide…

Global As pharma navigates issues ranging from the US Inflation Reduction Act to new EU pharmaceutical legislation, and the impact of global unrest on supply chains, the industry is experiencing other shifts as reflected in Pharma Exec’s 2024 Top 50 Companies. Based on 2023 drug revenue performance from global drug makers,…

Hong Kong Industry veteran Krish Sundaresan, GM for Hong Kong & Macau at Pfizer for the past two and a half years, shares his experience navigating the shifting dynamics brought on by the COVID-19 pandemic, enhancing omni-channel capabilities, and launching four new products in 2023 alone. Sundaresen also discusses the opportunity to…

Global Having been quietly working away on its mRNA platform for years, Moderna stepped into the limelight during the COVID-19 pandemic and became a commercial-stage outfit almost overnight with its vaccine. After generating sales of USD 18.4 billion in 2022, demand for the company’s Spikevax shot, still its only commercialized product…

China Amid geopolitical tensions and a drop in foreign investments, China continues to encourage international companies to increase their Chinese footprint. At this week’s China Development Forum (CDF), CEOs from Pfizer, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Novartis, and Takeda made it clear that Big Pharma’s interest in the country has…

Portugal While not a major player in clinical trials at the European level, Portugal has untapped potential in this field, leveraging a first pioneering centre in Braga, the country’s strong scientific community, a growing openness to collaboration with industry, and access to a European patient database. Considering the remarkable progress that…

Turkey A roundup of the biggest pharma and healthcare stories from Turkey including the investigation of 19 pharma companies by the country’s competition watchdog; Gen Pharma Caucasus Manufacturing’s new plant in Azerbaijan; drug shortages resulting from a newly adopted currency-indexed medication supply system, and the surge in upper respiratory tract infections…

USA The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) approved no less than 55 new drugs in 2023, a number surpassing that of 2022 by almost 50 percent. While 28 rare disease treatments and five novel gene therapies got the green light, the agency also…